Literature DB >> 20194249

Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Richard S E Keefe1, Sophia Vinogradov, Alice Medalia, Steven M Silverstein, Morris D Bell, Dwight Dickinson, Joseph Ventura, Stephen R Marder, T Scott Stroup.   

Abstract

The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills for patients who are engaged in pharmacologic trials to improve cognition. However, it is not clear how a cognitive remediation intervention would be employed in multisite clinical trials. A meeting of experts on cognitive remediation and related methodological topics was convened to address the feasibility and study design issues for the development of a multisite trial of cognitive remediation in schizophrenia called the Cognitive Remediation in the Schizophrenia Trials Network study. This report details the findings from this meeting, which included the following 4 conclusions. (1) A multisite trial of a cognitive remediation intervention using a network of diverse research sites would be of great scientific value. (2) Various interventions could be employed for this multisite trial. (3) Programs that do not address key motivational and interpersonal aspects of cognitive remediation may benefit from supplementation with "bridging groups" that allows patients to meet with others and to apply their newly acquired cognitive skills to everyday life. (4) Before a multisite efficacy trial is initiated, a pilot study could demonstrate the feasibility of conducting a trial using a cognitive remediation intervention.

Entities:  

Mesh:

Year:  2010        PMID: 20194249      PMCID: PMC3160227          DOI: 10.1093/schbul/sbq010

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  39 in total

Review 1.  Cognitive rehabilitation: how it is and how it might be.

Authors:  B A Wilson
Journal:  J Int Neuropsychol Soc       Date:  1997-09       Impact factor: 2.892

2.  Defining a cognitive function decrement in schizophrenia.

Authors:  Richard S E Keefe; Charles E Eesley; Margaret P Poe
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

3.  Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later.

Authors:  Melissa Fisher; Christine Holland; Karuna Subramaniam; Sophia Vinogradov
Journal:  Schizophr Bull       Date:  2009-03-05       Impact factor: 9.306

4.  Integrated psychological therapy (IPT) for schizophrenia: is it effective?

Authors:  Volker Roder; Daniel R Mueller; Kim T Mueser; Hans D Brenner
Journal:  Schizophr Bull       Date:  2006-08-17       Impact factor: 9.306

5.  The structure of coping.

Authors:  L I Pearlin; C Schooler
Journal:  J Health Soc Behav       Date:  1978-03

6.  Neuropsychological function in schizophrenia. Selective impairment in memory and learning.

Authors:  A J Saykin; R C Gur; R E Gur; P D Mozley; L H Mozley; S M Resnick; D B Kester; P Stafiniak
Journal:  Arch Gen Psychiatry       Date:  1991-07

7.  What predicts a good response to cognitive remediation interventions?

Authors:  Alice Medalia; Randall Richardson
Journal:  Schizophr Bull       Date:  2005-08-24       Impact factor: 9.306

8.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Authors:  Sophia Vinogradov; Melissa Fisher; Heather Warm; Christine Holland; Margaret A Kirshner; Bruce G Pollock
Journal:  Am J Psychiatry       Date:  2009-07-01       Impact factor: 18.112

9.  Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.

Authors:  Susan R McGurk; Michael F Green; William C Wirshing; Donna Ames Wirshing; Steven R Marder; Jim Mintz; Robert Kern
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

10.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Authors:  Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson
Journal:  Arch Gen Psychiatry       Date:  2007-10
View more
  27 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients.

Authors:  Daniel R Mueller; Stefanie J Schmidt; Volker Roder
Journal:  Schizophr Bull       Date:  2015-02-22       Impact factor: 9.306

3.  Compensatory cognitive training for psychosis: who benefits? Who stays in treatment?

Authors:  Elizabeth W Twamley; Cynthia Z Burton; Lea Vella
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

Review 4.  Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia.

Authors:  Melissa Fisher; Rachel Loewy; Kate Hardy; Danielle Schlosser; Sophia Vinogradov
Journal:  Annu Rev Clin Psychol       Date:  2013-01-07       Impact factor: 18.561

Review 5.  Cognitive training for impaired neural systems in neuropsychiatric illness.

Authors:  Sophia Vinogradov; Melissa Fisher; Etienne de Villers-Sidani
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

6.  Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Authors:  Richard S E Keefe; Sophia Vinogradov; Alice Medalia; Peter F Buckley; Stanley N Caroff; Deepak C D'Souza; Phillip D Harvey; Karen A Graham; Robert M Hamer; Stephen M Marder; Del D Miller; Stephen J Olson; Jayendra K Patel; Dawn Velligan; Trina M Walker; Adam J Haim; T Scott Stroup
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

Review 7.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

8.  Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.

Authors:  Jean A Frazier; Anthony J Giuliano; Jacqueline L Johnson; Lauren Yakutis; Eric A Youngstrom; David Breiger; Linmarie Sikich; Robert L Findling; Jon McClellan; Robert M Hamer; Benedetto Vitiello; Jeffrey A Lieberman; Stephen R Hooper
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-03-13       Impact factor: 8.829

9.  Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.

Authors:  Deepak C D'Souza; Rajiv Radhakrishnan; Edward Perry; Savita Bhakta; Nagendra M Singh; Richa Yadav; Danielle Abi-Saab; Brian Pittman; Santosh K Chaturvedi; Mahendra P Sharma; Morris Bell; Chittaranjan Andrade
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

Review 10.  Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.

Authors:  Philip D Harvey; Christopher R Bowie
Journal:  Psychiatr Clin North Am       Date:  2012-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.